argenx is a clinical-stage biotechnology company developing differentiated therapies for the treatment of severe autoimmune diseases and cancer. Co. is developing its main product candidate, efgartigimod, for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris and chronic demyelinating polyneuropathy, all of which are severe autoimmune diseases associated with high levels of circulating pathogenic immunoglobulin G antibodies for which there are few biologic treatments and a severe unmet medical need exists. Co. is also developing cusatuzumab in hematological cancer indications, acute myeloid leukemia, as well as high-risk myelodysplastic syndrome. The ARGX average annual return since 2017 is shown above.
The Average Annual Return on the ARGX average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ARGX average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ARGX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|